Related Experiment Video
Updated: Aug 12, 2025
10:02
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
32.4K
UNITED KINGDOM DATABASE STUDY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) FOR MACULAR EDEMA RELATED TO RETINAL
Mohamed Kamel Soliman1,2, Javier Zarranz-Ventura3, Usha Chakravarthy4
1Department of Ophthalmology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Retina (Philadelphia, Pa.)
|February 2, 2023
Summary
Intravitreal dexamethasone implant (IDI) effectively improved vision for macular edema due to retinal vein occlusion. While intraocular pressure increases occurred, especially in phakic eyes, they were manageable, showing real-world effectiveness comparable to clinical trials.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Macular edema secondary to retinal vein occlusion significantly impacts visual acuity.
- Intravitreal corticosteroid implants are a treatment option for this condition.
Purpose of the Study:
- To evaluate treatment patterns, visual outcomes, and safety of intravitreal dexamethasone implant (IDI) for macular edema in retinal vein occlusion.
- To assess real-world effectiveness and safety of IDI in a large patient cohort.
Main Methods:
- Retrospective analysis of anonymized electronic medical records from 16 centers.
- Inclusion of data on visual acuity, injection frequency, intraocular pressure (IOP) changes, IOP-lowering medication use, and cataract surgery rates.
- Data collected over up to 2 years for patients with central or branch retinal vein occlusion.
Main Results:
- Mean visual acuity improved from 20/125 to 20/40 after the first IDI injection.
- 15% of eyes underwent cataract surgery by 24 months.
- Higher incidence of IOP increase (≥10 mmHg) observed in phakic (14.2%) versus pseudophakic (5.4%) eyes; 0.2% required IOP filtering surgery.
Conclusions:
- Real-world visual outcomes with IDI for retinal vein occlusion-related macular edema are comparable to clinical trial results.
- Increased IOP in patients with pre-existing ocular hypertension or glaucoma can be managed with additional medical therapy.
- Phakic eyes may experience a higher frequency of IOP rise after IDI treatment compared to pseudophakic eyes.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
516
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
516
01:28Angle Closure Glaucoma: Treatment
604
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
604